Kaleido Biosciences Initiates Controlled Clinical Study with Massachusetts General Hospital of Microbiome Metabolic Therapy KB109 in Outpatients with Mild-to-Moderate COVID-19 - GlobeNewswire

Kaleido Biosciences Initiates Controlled Clinical Study with Massachusetts General Hospital of Microbiome Metabolic Therapy KB109 in Outpatients with Mild-to-Moderate COVID-19  GlobeNewswire

Comments

Post a Comment

Popular posts from this blog

Global Influenzavirus B Infection Drug Market 2019 - AbbVie Inc, Adimmune Corp, Altravax Inc, Amarillo Biosciences Inc, Aphios Corp Business Pulze - Business Pulze

Global Influenzavirus B Infection Drug Market 2019 - AbbVie Inc, Adimmune Corp, Altravax Inc, Amarillo Biosciences Inc, Aphios Corp Business Pulze    Business Pulze Recently we have published research report on the Global Influenzavirus B Infection Drug Market 2014-2026 with a detailed analysis of the current ...
Read more

Healthcare layoff tracker—Walmart cuts 74 virtual health jobs - Fierce healthcare

Image
Last year, the Fierce Healthcare team compiled a running tally of layoffs across the industry, as well as ongoing updates from hospitals specifically as they emerged from a financially damaging 2022. Now, we're doing the same for similar workforce changes in 2024. Stick with this tracker for the latest updates, and reach out to the team with any layoff news. UPDATED at 1:25 p.m. on June 3 Cigna has laid off 261 employees in Arizona, according to a filing with the state. The layoffs, which take place in the insurer's Evernorth Care Group, was issued as a Worker Adjustment and Retraining Notification (WARN) Act notice dated Friday, May 31. Cigna will provide transition services to the affected workers. "Evernorth Care Group remains highly committed to serving our patients in Arizona, and we will continue to provide high-quality, affordable care and exceptional service," said an Evernorth spokesperson. "Our comprehensive integrated pr...
Read more